npj Parkinsons Dis: Metabolite and lipid studies revealing oxidative stress status in emerging Parkinson's disease

Parkinson's disease (PD) is the second most prevalent neurodegenerative disease after Alzheimer's disease, affecting 1% of the population over the age of 60 and contributing significantly to increased public health costs
.

Although metabolic disorders in Parkinson's disease have been investigated over the years, their pathogenesis, disease progression, and efficacy of drug therapy on disease evolution still require further exploration

Parkinson's disease (PD) is the second most prevalent neurodegenerative disease after Alzheimer's disease, affecting 1% of the population over the age of 60 and contributing significantly to increased public health costs

Currently, routine analytical tests do not provide enough information to identify reliable blood biomarkers to detect early symptoms of PD, monitor disease progression, and detect the effects of therapeutic interventions

Figure 1 Title map of the paper

Figure 1 Title map of the paper

Metabolomics has become a powerful tool to characterize the biochemical characteristics of the pathogenesis of different diseases and provides useful applications in the biomedical field
.

Nuclear magnetic resonance (NMR) is one of the most commonly used analytical techniques in metabolomic investigations, and in the context of molecular medicine, it has been shown to be effective in characterizing the metabolic composition of different biological samples

Metabolomics has become a powerful tool to characterize the biochemical characteristics of the pathogenesis of different diseases and provides useful applications in the biomedical field

To date, few metabolomic studies have focused on new drug-free PD patients (dn2PD)

From this, Gaia Meoni et al.

Figure 2 Metabolite change results

Figure 2 Metabolite change results

 

To this end, they included 307 subjects, including dn2PD (n = 228) and healthy controls (CTR, n = 79), split across two large independent training and validation cohorts
.

What is special about this collection is that there are many dn2PD patients to explore the pathological serum biochemistry independent of the effect of antidopaminergic therapy

To this end, they included 307 subjects, including dn2PD (n = 228) and healthy controls (CTR, n = 79), split across two large independent training and validation cohorts

Additionally, a cohort of 22 advanced PD patients receiving dopaminergic therapy (AdvPD) was included to examine and test for serovar changes in disease progression

They used multivariate and univariate methods to infer the characteristics of metabolite and lipoprotein profiles in newly diagnosed PD patients who did not respond to new drugs, and were also related to the biological sex of the study subjects, demonstrating that the pathological indicators were more pronounced in male patients

Additionally, the presence of a validation cohort allowed them to confirm alterations in acetone and cholesterol levels in male PD patients

Source:
Meoni G, Tenori L, Schade S, et al.

Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson's disease patients.
npj Parkinsons Dis.
2022;8(1):14.
doi :10.
1038/s41531-021-00274-8

Source:
Meoni G, Tenori L, Schade S, et al.
Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson's disease patients.
npj Parkinsons Dis.
2022;8(1):14.
doi :10.
1038/s41531-021-00274-8Leave a message here